NEWS RELEASE TRANSMITTED BY Marketwire
FOR: Abattis Bioceuticals Corp.
CNSX SYMBOL: FLU
Abattis Announces National Distribution Agreement with Hedley Enterprises Ltd.
MAY 3, 2012 - 08:00 ET
-- 5 year Agreement
-- Hedley will distribute and market Abattis' products across Canada
-- Hedley has an established distribution channel of 2,400 retail outlets
-- Agreement will result in Abattis' first source of revenue
VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 3, 2012) - Abattis Biologix Corporation (the "Company" or "Abattis") (CNSX:FLU), has entered into an exclusive distribution agreement (the "Agreement") with Hedley Enterprises Ltd. ("Hedley") to purchase, resell and distribute Abattis' line of natural products in Canada. Under the terms of the Agreement Hedley has acquired the exclusive right to sell and distribute Abattis' products to all retail distribution channels including: health food stores, grocery stores, fitness facilities, and similar retail establishments. Hedley has existing sales channels into 2,400 retail outlets across Canada.
"We are excited to be working with Hedley Enterprises and to have them introduce and market our products to the Canadian market. This agreement will result in our first source of revenue," said Mike Withrow, President and CEO of Abattis.
About Hedley Enterprises Ltd.
Hedley specializes in distributing unique and proprietary natural health products. Hedley Enterprises Ltd. was founded July 1, 1977 by Bob Hedley. Throughout this time, Bob has come to realize that superior service must be the number one priority in order to provide a quality product in a place of business where people feel welcome and cared for. As a result, re-sellers enjoy this superior service throughout the company.
About Abattis Biologix Corporation
Abattis Biologix Corporation is a specialty bio-technology life sciences company that has acquired intellectual property, conducts research, and works to develop proprietary health and wellness solutions that address chronic illnesses and disease in animals and humans through proprietary and patent pending formulations. The Company has identified targeted channels to market and license proprietary patent pending products throughout the world.
ON BEHALF OF THE COMPANY
Mike Withrow, Director